Related Experiment Video

Updated: Sep 23, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

The loss of TGF-beta signaling promotes prostate cancer metastasis

William H Tu1, Tania Z Thomas, Naoya Masumori

  • 1Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA. william.tu@vanderbilt.edu

Neoplasia (New York, N.Y.)
|July 19, 2003
PubMed

Insights

Disrupting transforming growth factor (TGF)-beta signaling in prostate cancer promotes metastasis. Inhibiting the TGF-beta type II receptor (T beta R II) in mice led to increased cancer spread, not tumor size.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Transforming growth factor (TGF)-beta signaling exhibits dual roles in cancer, initially inhibiting then promoting tumor progression.
  • Loss of the TGF-beta type II receptor (T beta R II) is linked to higher tumor grade in human prostate cancer.
  • The precise role of TGF-beta pathway disruption in prostate cancer metastasis remains unclear.

Purpose of the Study:

  • To investigate the causal effect of an inhibited TGF-beta pathway on prostate cancer development and metastasis.
  • To model prostate cancer progression using transgenic mice with specific genetic modifications.

Main Methods:

  • Generated transgenic mice expressing SV40 large T antigen and a dominant-negative T beta R II mutant in the prostate.
  • Assessed transgene expression and TGF-beta 1 levels in prostate tissue.
  • Measured protein levels of plasminogen activator inhibitor type I as a marker for TGF-beta signaling activity.
  • Quantified tumor size and metastasis in experimental and control groups.

Main Results:

  • Expression of both transgenes and TGF-beta 1 was confirmed in the prostate.
  • Decreased plasminogen activator inhibitor type I levels correlated with dominant-negative T beta R II expression, indicating pathway inhibition.
  • Mice with disrupted TGF-beta signaling showed increased metastasis compared to controls.
  • Tumor size was not significantly affected by the disruption of TGF-beta signaling.

Conclusions:

  • Disruption of TGF-beta signaling plays a causal role in promoting prostate cancer metastasis.
  • Inhibition of the TGF-beta pathway can enhance cancer cell motility and spread without necessarily increasing primary tumor size.
  • These findings highlight the critical role of TGF-beta signaling in regulating prostate cancer progression and metastasis.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...